{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:19:52Z","timestamp":1784074792976,"version":"3.55.0"},"reference-count":44,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"unspecified","delay-in-days":120,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N\/a. Pfizer Inc provided medication for the study."],"award-info":[{"award-number":["N\/a. Pfizer Inc provided medication for the study."]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2025,10,5]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the pharmacokinetics, effectiveness, safety and tolerability of tofacitinib in young adults with active mucocutaneous (MC) SLE manifestations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with SLE and Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity (CLASI-A) Scores &gt;8 newly received open-label tofacitinib from baseline to week (week) 72. Intensive pharmacokinetics sampling was done at the end of week 1, and safety was assessed throughout the study. The primary effectiveness endpoint was partial response of MC activity defined as &lt;20% improvement of the CLASI-A Score from baseline (CLASI-PR) at week 8 in intention-to-treat analysis; secondary and other endpoints included MC complete response (CLASI-CR; CLASI-A=0) and quality of life (QoL) as measured by Skindex-29.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Subjects were 11 patients (female patients: 10, mean\u00b1SD age: 23.0\u00b15.87 years) with moderate to severe MC manifestations (CLASI-A=16.6\u00b18.03). The pharmacokinetics of tofacitinib was comparable to that seen in juvenile and adult arthritis. During 629 patient-weeks of follow-up, 73 adverse events (AEs) were reported, none of which were considered severe or led to study discontinuation. There were three serious AEs (pelvic inflammatory disease, appendicitis and migraine with aura) but no major cardiovascular events, malignancies or death. In intention-to-treat analysis, at week 8 CLASI-PR was achieved in 73% (8\/11) of subjects, in 82% at week 24 and 100% at week 72, respectively. Although CLASI-A Scores significantly decreased from baseline (baseline\/week 8\/week 24\/week 72=16.55\u00b18.03\/8.64\u00b17.8\/8.82+7 .9\/7+9.7; p&lt;0.001), CLASI-CR was achieved by only &lt;10% (1\/11), starting week 8. Skindex-29 Scores improved significantly as early as week 4 (baseline\/week 4\/week 24\/week 72= 37.6\u00b124.16\/26.1\u00b123.58\/24.3\u00b128.67\/25.5\u00b130.71; p=0.009).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tofacitinib in patients with SLE with active MC manifestations showed good effectiveness by week 4 as well as tolerability at exposure comparable to those with other rheumatic diseases. Tofacitinib was associated with significant improvement of QoL due to rapid improvement of MC inflammation. Observed safety and pharmacokinetics were comparable to observations in juvenile and adult arthritis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2025-001689","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:50:25Z","timestamp":1761810625000},"page":"e001689","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics, effectiveness, tolerability and effect on quality of life of open-label tofacitinib for the treatment of moderately active mucocutaneous manifestations of SLE: results of a 76-week phase II study"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3514-7662","authenticated-orcid":false,"given":"Ivanna","family":"Romankevych","sequence":"first","affiliation":[{"name":"Rheumatology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7041-723X","authenticated-orcid":false,"given":"Nora","family":"Singer","sequence":"additional","affiliation":[{"name":"Rheumatology, The MetroHealth System, Cleveland, Ohio, USA"},{"name":"MetroHealth Rheumatology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Huggins","sequence":"additional","affiliation":[{"name":"Rheumatology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyani","family":"Marathe","sequence":"additional","affiliation":[{"name":"Dermatology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Merritt","sequence":"additional","affiliation":[{"name":"Rheumatology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[{"name":"Pediatrics, Epidemiology & Biostatistics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Stockert","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Pelletier","sequence":"additional","affiliation":[{"name":"Pfizer Global, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxing","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer Global, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Shi","sequence":"additional","affiliation":[{"name":"Pfizer Global, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Huang","sequence":"additional","affiliation":[{"name":"Biostatistics & Epidemiology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-2987","authenticated-orcid":false,"given":"Hermine","family":"Brunner","sequence":"additional","affiliation":[{"name":"Rheumatology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"2026010700554823000_12.2.e001689.1","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.17787.1","article-title":"Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus","volume":"8","author":"Chen","year":"2019","journal-title":"F1000Res"},{"key":"2026010700554823000_12.2.e001689.2","doi-asserted-by":"crossref","DOI":"10.21037\/atm-20-5048","article-title":"The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review","volume":"9","author":"Chakka","year":"2021","journal-title":"Ann Transl Med"},{"key":"2026010700554823000_12.2.e001689.3","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.435"},{"key":"2026010700554823000_12.2.e001689.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)61689-6"},{"key":"2026010700554823000_12.2.e001689.5","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2022.778934","article-title":"Using Gene Expression Analysis to Understand Complex Autoimmune Skin Disease Patients: A Series of Four Canine Cutaneous Lupus Erythematosus Cases","volume":"9","author":"Amudzi","year":"2022","journal-title":"Front Vet Sci"},{"key":"2026010700554823000_12.2.e001689.6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrrheum.2015.106","article-title":"Pathogenesis and targeted treatment of skin injury in SLE","volume":"11","author":"Deng","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2026010700554823000_12.2.e001689.7","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026010700554823000_12.2.e001689.8","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun"},{"key":"2026010700554823000_12.2.e001689.9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-50379-8","article-title":"Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study","volume":"14","author":"Martinez-Molina","year":"2024","journal-title":"Sci Rep"},{"key":"2026010700554823000_12.2.e001689.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00726-8"},{"key":"2026010700554823000_12.2.e001689.11","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/1756-185X.14324","article-title":"Efficacy and safety of tofacitinib in the treatment of refractory cases of polyarticular course juvenile idiopathic arthritis: A study from Bangladesh","volume":"25","author":"Rahman","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"2026010700554823000_12.2.e001689.12","doi-asserted-by":"publisher","DOI":"10.1016\/bs.apha.2015.03.005"},{"key":"2026010700554823000_12.2.e001689.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04181-2"},{"key":"2026010700554823000_12.2.e001689.14","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2026010700554823000_12.2.e001689.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01255-1"},{"key":"2026010700554823000_12.2.e001689.16","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-017-0212-y","article-title":"Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study","volume":"15","author":"Ruperto","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026010700554823000_12.2.e001689.17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg382"},{"key":"2026010700554823000_12.2.e001689.18","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/jid.2011.138","article-title":"Interpretation of Skindex-29 scores: cutoffs for mild, moderate, and severe impairment of health-related quality of life","volume":"131","author":"Prinsen","year":"2011","journal-title":"J Invest Dermatol"},{"key":"2026010700554823000_12.2.e001689.19","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/jid.2009.404","article-title":"Health-related quality of life assessment in dermatology: interpretation of Skindex-29 scores using patient-based anchors","volume":"130","author":"Prinsen","year":"2010","journal-title":"J Invest Dermatol"},{"key":"2026010700554823000_12.2.e001689.20","unstructured":"Banding and the clinical interpretation of Skindex-29 scores using an anchor based technique. J Am Acad Dermatol 2010."},{"key":"2026010700554823000_12.2.e001689.21","unstructured":"MSSO M . Medical Dictionary for Regulatory Medical Activities,: MedDRA MSSO, 2025. Available: https:\/\/www.meddra.org"},{"key":"2026010700554823000_12.2.e001689.22","first-page":"19","volume-title":"US Department of Health and Human Services NIoH","volume":"2017","year":"2017"},{"key":"2026010700554823000_12.2.e001689.23","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001595","article-title":"Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37\u2009066 patient-years of tofacitinib exposure","volume":"7","author":"Burmester","year":"2021","journal-title":"RMD Open"},{"key":"2026010700554823000_12.2.e001689.24","doi-asserted-by":"crossref","unstructured":"Nahler G , Nahler G . Adverse event of special interest. Dictionary of Pharmaceutical Medicine 2009.:4. doi:10.1007\/978-3-211-89836-9_36","DOI":"10.1007\/978-3-211-89836-9_36"},{"key":"2026010700554823000_12.2.e001689.25","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2026010700554823000_12.2.e001689.26","first-page":"373","article-title":"The Systemic Lupus International Collaborating Clinics\/American College of Rheumatology (SLICC\/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison","volume":"27","author":"Gladman","year":"2000","journal-title":"J Rheumatol"},{"key":"2026010700554823000_12.2.e001689.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23889.x"},{"key":"2026010700554823000_12.2.e001689.28","unstructured":"Classification of disease activity and damage in cutaneous lupus. In: ARTHRITIS & RHEUMATOLOGY. WILEY 111 RIVER STHOBOKEN 07030-5774, NJ USA, 2021."},{"key":"2026010700554823000_12.2.e001689.29","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000365","article-title":"Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures","volume":"6","author":"Thanou","year":"2019","journal-title":"Lupus Sci Med"},{"key":"2026010700554823000_12.2.e001689.30","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.122.001018"},{"key":"2026010700554823000_12.2.e001689.31","doi-asserted-by":"crossref","first-page":"103440","DOI":"10.1016\/j.autrev.2023.103440","article-title":"Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: A systematic review and meta-analysis","volume":"22","author":"Ma","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2026010700554823000_12.2.e001689.32","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10061242","article-title":"Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease","volume":"10","author":"Restellini","year":"2021","journal-title":"J Clin Med"},{"key":"2026010700554823000_12.2.e001689.33","unstructured":"The renal activity index for lupus (rail) identifies active renal disease in sle patients and its longitudinal score associates with renal responses in lupus nephritis. In: ARTHRITIS & RHEUMATOLOGY;. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, 2022."},{"key":"2026010700554823000_12.2.e001689.34","doi-asserted-by":"crossref","first-page":"464","DOI":"10.5414\/CP203516","article-title":"Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis","volume":"57","author":"Xie","year":"2019","journal-title":"CP"},{"key":"2026010700554823000_12.2.e001689.35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cpdd.899","article-title":"Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis","volume":"10","author":"Vong","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026010700554823000_12.2.e001689.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02546-6"},{"key":"2026010700554823000_12.2.e001689.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31363-1"},{"key":"2026010700554823000_12.2.e001689.38","first-page":"1109","article-title":"Tofacitinib versus thalidomide for mucocutaneous lesions of systemic lupus erythematosus: A real-world CSTAR cohort study XXVII","volume":"33","author":"Zhao","year":"2024","journal-title":"Lupus (Los Angel)"},{"key":"2026010700554823000_12.2.e001689.39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200726"},{"key":"2026010700554823000_12.2.e001689.40","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222259"},{"key":"2026010700554823000_12.2.e001689.41","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180722"},{"key":"2026010700554823000_12.2.e001689.42","doi-asserted-by":"crossref","unstructured":"Cardelli C , Elefante E , Signorini V , et al . P122\u2005Skin disease burden in systemic lupus erythematosus: data from a monocentric cohort. 14th European Lupus Meeting, Bruges, Belgium, March 19\u201322, 2024, March 2024 doi:10.1136\/lupus-2024-el.176","DOI":"10.1136\/lupus-2024-el.176"},{"key":"2026010700554823000_12.2.e001689.43","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.2825"},{"key":"2026010700554823000_12.2.e001689.44","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13709"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2025-001689","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:56:36Z","timestamp":1767776196000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2025-001689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,10,29]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/lupus-2025-001689"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2025-001689","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}